GlassScriptPhysician profile
Steven A Kolenik
NPI 1649292798
$7,356.93
in general payments reported to CMS, 2019-2025
30 companies · $2,285 in 2025
The $2,285 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $158 · 2021: $282 · 2022: $482 · 2023: $1,465 · 2024: $1,613 · 2025: $2,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,363.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,363.28 | 2019-2025 | |
| Janssen Biotech, INC. | $1,327.49 | 2019-2025 | Tremfya |
| Ucb, INC. | $741.96 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $715.80 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $393.26 | 2019-2025 | |
| Genzyme Corporation | $301.74 | 2019-2025 | |
| Leo Pharma INC. | $275.43 | 2024-2025 | Anzupgo, Adbry |
| Pfizer INC. | $264.37 | 2020-2025 | |
| Genentech USA, INC. | $260.40 | 2019-2024 | Erivedge |
| Merz North America, INC. | $221.01 | 2019 | |
| Allergan, INC. | $190.45 | 2019-2020 | |
| Galderma Laboratories, L.P. | $188.26 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $138.22 | 2023-2025 | Jublia, Cabtreo |
| Strata Skin Sciences, INC. | $131.43 | 2019-2024 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $123.82 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $115.82 | 2020-2025 | Sotyktu |
| Blueprint Medicines Corporation | $99.16 | 2023-2024 | Ayvakit |
| Amgen INC. | $97.91 | 2019-2025 | Otezla |
| Biofrontera INC. | $82.61 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Medtronic Vascular, INC. | $59.29 | 2020 | |
| Incyte Corporation | $58.82 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $38.50 | 2023 | Ilumya, Absorica Ld, Winlevi |
| Botanix Sb INC | $25.46 | 2025 | Sofdra |
| Medtronic, INC. | $24.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.88 | 2025 | Spevigo |
| Lilly USA, LLC | $22.73 | 2024 | Taltz |
| Almirall LLC | $22.35 | 2022 | |
| Verrica Pharmaceuticals INC. | $21.90 | 2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $17.19 | 2024 | Zoryve |
| Organon LLC | $10.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kolenik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.